Literature DB >> 8686754

Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.

D R Senger1, S R Ledbetter, K P Claffey, A Papadopoulos-Sergiou, C A Peruzzi, M Detmar.   

Abstract

We have identified several mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) likely regulates endothelial cells (EC) migration. VPF/VEGF induced dermal microvascular EC expression of mRNAs encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface, and VPF/VEGF also induced mRNA encoding osteopontin (OPN), an alphavbeta3 ligand. OPN promoted EC migration in vitro; and VPF/VEGF induction of alphavbeta3 was accompanied by increased EC migration toward OPN. Because thrombin cleavage of OPN results in substantial enhancement of OPN's adhesive properties, and because VPF/VEGF promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway, we also investigated whether VPF/VEGF facilitates thrombin cleavage of OPN in vivo. Consistent with this hypothesis, co-injection of VPF/VEGF together with OPN resulted in rapid cleavage of OPN by endogenous thrombin. Furthermore, in comparison with native OPN, thrombin-cleaved OPN stimulated a greater rate of EC migration in vitro, which was additive to the increased migration associated with induction of alpha v beta 3. Thus, these data demonstrate cooperative mechanisms for VPF/VEGF regulation of EC migration involving the alphavbeta3 integrin, the alphavbeta3 ligand OPN, and thrombin cleavage of OPN. These findings also illustrate an operational link between VPF/VEGF induction of EC gene expression and VPF/VEGF enhancement of microvascular permeability, suggesting that these distinct biological activities may act accordingly to stimulate EC migration during angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8686754      PMCID: PMC1865227     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  78 in total

1.  Monoclonal antibody and synthetic peptide inhibitors of human tumor cell migration.

Authors:  K M Yamada; D W Kennedy; S S Yamada; H Gralnick; W T Chen; S K Akiyama
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

2.  Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin.

Authors:  D R Senger; C A Perruzzi; A Papadopoulos; D G Tenen
Journal:  Biochim Biophys Acta       Date:  1989-06-13

3.  The cDNA and derived amino acid sequence for human osteopontin.

Authors:  M C Kiefer; D M Bauer; P J Barr
Journal:  Nucleic Acids Res       Date:  1989-04-25       Impact factor: 16.971

4.  Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells.

Authors:  D Gospodarowicz; J A Abraham; J Schilling
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

5.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

Authors:  N Ferrara; W J Henzel
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

6.  Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.

Authors:  D T Connolly; D M Heuvelman; R Nelson; J V Olander; B L Eppley; J J Delfino; N R Siegel; R M Leimgruber; J Feder
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

7.  Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

Authors:  D R Senger; D T Connolly; L Van de Water; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1990-03-15       Impact factor: 12.701

8.  Effects of recombinant tumor necrosis factor-alpha on cultured microvascular endothelial cells derived from human dermis.

Authors:  M Detmar; E Imcke; Z Ruszczak; C E Orfanos
Journal:  J Invest Dermatol       Date:  1990-12       Impact factor: 8.551

Review 9.  Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.

Authors:  D R Senger; C A Perruzzi; A Papadopoulos
Journal:  Anticancer Res       Date:  1989 Sep-Oct       Impact factor: 2.480

10.  Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization.

Authors:  S K Akiyama; S S Yamada; W T Chen; K M Yamada
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

View more
  121 in total

1.  VEGF expression by epithelial and stromal cell compartments: resolving a controversy.

Authors:  D R Senger; L Van De Water
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 2.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.

Authors:  D T Denhardt; M Noda; A W O'Regan; D Pavlin; J S Berman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 3.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

4.  Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries.

Authors:  T Couffinhal; M Kearney; B Witzenbichler; D Chen; T Murohara; D W Losordo; J Symes; J M Isner
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

5.  Rho activity critically and selectively regulates endothelial cell organization during angiogenesis.

Authors:  Mien V Hoang; Mary C Whelan; Donald R Senger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

6.  Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty.

Authors:  D Panda; G C Kundu; B I Lee; A Peri; D Fohl; I Chackalaparampil; B B Mukherjee; X D Li; D C Mukherjee; S Seides; J Rosenberg; K Stark; A B Mukherjee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

7.  Insufficient Angiogenesis: Cause of Abnormally Thin Endometrium in Subfertile Patients?

Authors:  Joachim Alfer; Lars Happel; Ralf Dittrich; Matthias W Beckmann; Arndt Hartmann; Andreas Gaumann; Volker U Buck; Irmgard Classen-Linke
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-07-17       Impact factor: 2.915

8.  A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.

Authors:  C Ostheimer; M Bache; A Güttler; M Kotzsch; D Vordermark
Journal:  Strahlenther Onkol       Date:  2013-12-11       Impact factor: 3.621

9.  VEGF-A and VEGFR1 SNPs associate with preeclampsia in a Philippine population.

Authors:  Melissa D Amosco; Van Anthony M Villar; Justin Michael A Naniong; Lara Marie G David-Bustamante; Pedro A Jose; Cynthia P Palmes-Saloma
Journal:  Clin Exp Hypertens       Date:  2016-09-26       Impact factor: 1.749

10.  Distinct role of PLCbeta3 in VEGF-mediated directional migration and vascular sprouting.

Authors:  Resham Bhattacharya; Junhye Kwon; Xiujuan Li; Enfeng Wang; Sujata Patra; John Paul Bida; Zeljko Bajzer; Lena Claesson-Welsh; Debabrata Mukhopadhyay
Journal:  J Cell Sci       Date:  2009-04-01       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.